Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tivozanib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 20/20 | 0.97 |
| ▸ | FLT1 known ✓ | P17948 | 4/20 | 0.97 |
| ▸ | FLT4 known ✓ | P35916 | 4/20 | 0.97 |
| ▸ | KIT known ✓ | P10721 | 3/20 | 0.97 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.97 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.97 |
| ▸ | EPHB2 | P29323 | 2/20 | 0.97 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.97 |
| ▸ | STK10 | O94804 | 2/20 | 0.97 |
| ▸ | ABL1 | P00519 | 2/20 | 0.97 |
| ▸ | RET | P07949 | 2/20 | 0.97 |
| ▸ | BCR | P11274 | 2/20 | 0.97 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.97 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.97 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.97 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.97 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.97 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.97 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tivozanib SCHEMBL29394095 | 1.00 | KDR (0.97) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL1869882 | 0.99 | KDR (0.98) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL30993908 | 0.99 | KDR (0.98) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL29354604 | 0.98 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL172883 | 0.98 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL29354238 | 0.98 | KDR (1.00) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5214691 | 0.95 | KDR (0.93) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5209537 | 0.95 | KDR (0.93) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5211590 | 0.93 | KDR (0.90) | KDRPDGFRAFLT1FLT4KIT | |
| Tivozanib SCHEMBL5545131 | 0.93 | KDR (0.90) | KDRPDGFRAFLT1FLT4KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 387 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20250339421-A1 | METHODS FOR TREATING BILE DUCT CANCERS WITH TIVOZANIB | THE U.S.A., AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-11-06 | — | — | US | claimed |
| EP-4637821-A1 | HER3 RADIOIMMUNOTHERAPY FOR THE TREATMENT OF SOLID CANCERS | Actinium Pharmaceuticals, Inc. (US) | 2025-10-29 | — | — | EP | claimed |
| EP-4612497-A2 | METHODS OF TREATING A TUMOR | Surface Oncology, LLC (US) | 2025-09-10 | — | — | EP | claimed |
| US-20250275955-A1 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER | AVEO PHARMACEUTICALS INC (US) | 2025-09-04 | — | — | US | claimed |
| US-20250242046-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | MALCOLM THOMAS (US) | 2025-07-31 | — | — | US | claimed |
| EP-4532024-A1 | ALLOGENEIC HYPOIMMUNE BIOMIMETIC NANOVESICLE FOR THE TREATMENT OF CANCER | Malcolm, Thomas (US) | 2025-04-09 | — | — | EP | claimed |
| EP-4522764-A1 | METHODS AND SYSTEMS FOR PREDICTING AN ORIGIN OF AN ALTERATION IN A SAMPLE USING A STATISTICAL MODEL | Foundation Medicine, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| CN-119546336-A | Allo-low immunity bionic nano vesicle for treating cancer | T·马尔科姆 | 2025-02-28 | — | — | CN | claimed |
| WO-2024231899-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2024-11-14 | — | — | WO | claimed |
| WO-2023136837-A1 | USE OF TIVOZANIB AND DURVALUMAB FOR TREATING HEPATOCELLULAR CARCINOMA (HCC) | AVEO PHARMACEUTICALS, INC. (US) | 2023-07-20 | — | — | WO | claimed |
| US-20230181589-A1 | PRMT5 INHIBITORS FOR OCULAR THERAPY | NATIONAL INSTITUTES OF HEALTH | 2023-06-15 | — | — | US | claimed |
| WO-2023096651-A1 | METHODS FOR TREATING BILE DUCT CANCERS WITH TIVOZANIB | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-06-01 | — | — | WO | claimed |
| US-20230042258-A1 | ANTI-IL-27 ANTIBODIES AND USES THEREOF | Surface Oncology, Inc. (US) | 2023-02-09 | — | — | US | claimed |
| US-11504365-B2 | Use of tivozanib to treat subjects with refractory cancer | AVEO PHARMACEUTICALS, INC. (US) | 2022-11-22 | — | — | US | claimed |
| EP-4087607-A1 | ANTI-CCR8 ANTIBODIES AND USES THEREOF | Vaccinex, Inc. (US) | 2022-11-16 | — | — | EP | claimed |
| WO-2022236134-A1 | ANTI-IL-27 ANTIBODIES AND USES THEREOF | Surface Oncology, Inc. (US) | 2022-11-10 | — | — | WO | claimed |
| EP-4034559-A1 | ANTI-IL-27 ANTIBODIES AND USES THEREOF | Surface Oncology, Inc. (US) | 2022-08-03 | — | — | EP | claimed |
| US-20220233516-A1 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER | AVEO PHARMACEUTICALS, INC. | 2022-07-28 | — | — | US | claimed |
| EP-4000634-A1 | MEDICINAL COMPOSITION COMPRISING TIVOZANIB | Kyowa Kirin Co., Ltd. (JP) | 2022-05-25 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250275955-A1 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER | PBK, PDCD1LG2, CD274 | KDR 119/4885FLT1 678/4885FLT4 258/4885 |
| US-20250339421-A1 | METHODS FOR TREATING BILE DUCT CANCERS WITH TIVOZANIB | SLK, XPO7, XPO5 | KDR 3297/4885FLT1 3406/4885FLT4 2316/4885 |
| US-20220233516-A1 | USE OF TIVOZANIB TO TREAT SUBJECTS WITH REFRACTORY CANCER | PBK, PDCD1LG2, CD274 | KDR 119/4885FLT1 678/4885FLT4 258/4885 |
| US-11504365-B2 | Use of tivozanib to treat subjects with refractory cancer | PBK, PDCD1LG2, CD274 | KDR 119/4885FLT1 678/4885FLT4 258/4885 |
| US-20230181589-A1 | PRMT5 INHIBITORS FOR OCULAR THERAPY | PRMT5, PRMT1, PRMT3 | KDR 45/4885FLT1 35/4885FLT4 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.